{"nctId":"NCT01682876","briefTitle":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","startDateStruct":{"date":"2012-10-07","type":"ACTUAL"},"conditions":["Meningococcal Disease","Infections, Meningococcal"],"count":715,"armGroups":[{"label":"2 through 5 years (1 Vac) MenACWY-CRM 1","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: MenACWY-CRM"]},{"label":"2 through 5 years (2 Vac) MenACWY-CRM 2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenACWY-CRM"]},{"label":"6 through 10 years (1 Vac) MenACWY-CRM 3","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: MenACWY-CRM"]},{"label":"6 through 10 years (2 Vac) MenACWY-CRM 4","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenACWY-CRM"]}],"interventions":[{"name":"MenACWY-CRM","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy children, 2 to 10 years of age who have up to date routine childhood vaccination, according to U.S. ACIP recommendations\n\nExclusion Criteria:\n\n1. Unwilling or unable to give written informed assent or consent to participate in the study.\n2. Perceived to be unreliable or unavailable for the duration of the study period.\n3. Previous confirmed or suspected disease caused by N. meningitidis.\n4. Previously immunized with a meningococcal vaccine (licensed or investigational).\n5. Receipt of any investigational or non-registered product within 30 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study.\n6. Receipt or plan to receive any vaccines within 30 days before and after administration of each dose of the study vaccine.\n\n   (certain exceptions influenza vaccines apply)\n7. Significant acute infection within the 7 days prior to enrolment or body temperature of 38°C or greater within 3 days prior to enrolment.\n8. Previous serious acute, chronic or progressive disease, epilepsy or any progressive neurological disease or history of Guillain-Barre syndrome.\n9. History of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components\n10. Impairment/alteration of immune function, either congenital or acquired or resulting from (for example):\n\n    * receipt of immunosuppressive therapy,\n    * receipt of immunostimulants,\n    * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives.\n11. Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination","description":"Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 97.5% Clopper-Pearson confidence interval (CI), directed against N. meningitidis serogroups A, C, W and Y, by serum bactericidal assay using human complement (hSBA) at 1 month after one vaccination or two vaccinations of MenACWY-CRM given two months apart. Seroresponse is defined as: a. postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer \\<1:4; b. for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]}]},{"type":"PRIMARY","title":"Superiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination","description":"Immunogenicity was measured as the percentage of subjects with overall seroresponse and associated 2-sided 95% CI, directed against N. meningitidis serogroups A, C, W and Y, by hSBA at 1 month after one vaccination or two vaccinations of MenACWY-CRM. Seroresponse -postvaccination hSBA titer ≥1:8 for subjects with a prevaccination hSBA titer \\<1:4 and for subjects with a prevaccination hSBA ≥1:4, an increase of at least four times of the prevaccination hSBA titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"89","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM","description":"Immunogenicity was measured as the percentage of subjects who achieved hSBA titer ≥1:8 and associated 95% CI, at one month after one vaccination or two vaccinations of MenACWY-CRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"96","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Month After One or Two Vaccination(s) of MenACWY-CRM","description":"Immunogenicity was measured as hSBA geometric mean titers (GMTs) and 95% CI against N. meningitidis serogroups A, C, W and Y, one month after one vaccination or two vaccinations of MenACWY-CRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"165","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"169","spread":null},{"groupId":"OG003","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"76","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA Titer ≥1:8, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM","description":"Immunogenicity was measured as the percentage of subjects with hSBA titer ≥1:8 and associated 95% CI at one year after one vaccination or two vaccinations of MenACWY-CRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Subjects, Directed Against N. Meningitidis Serogroups A, C, W and Y At One Year After One or Two Vaccination(s) of MenACWY-CRM","description":"Immunogenicity was measured as hSBA GMTs and 95% CI against N. meningitidis serogroups A, C, W and Y at one year after one vaccination or two vaccinations of MenACWY-CRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.72","spread":null},{"groupId":"OG001","value":"2.66","spread":null},{"groupId":"OG002","value":"4.66","spread":null},{"groupId":"OG003","value":"3.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7.03","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9.88","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of 2 to 5 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination","description":"Safety was assessed as the number of 2 to 5 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Numbers of 6 to 10 Years-Old Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination","description":"Safety was assessed as the number of 6 to 10 years-old subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after one or two vaccination(s) of MenACWY-CRM","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Selected AEs After Any Vaccination","description":"Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 86 after one or two vaccination(s) of MenACWY-CRM","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Selected AEs After Any Vaccination","description":"Safety was assessed as the number subjects who reported Selected AEs from day 1 up to day 422 after one or two vaccination(s) of MenACWY-CRM","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":179},"commonTop":["INJECTION SITE PAIN","INJECTION SITE ERYTHEMA","INJECTION SITE INDURATION","PYREXIA","MYALGIA"]}}}